Basic Information
SUSTANON 250 INJECTION
INJECTION
Regulatory Information
SIN04555P
May 31, 1990
Prescription Only
Therapeutic
INTRAMUSCULAR
August 10, 2023
June 4, 2025
XG03BA03
Company Information
Active Ingredients
Strength: 30 mg/ml
Strength: 100 mg/ml
Strength: 60 mg/ml
Strength: 60 mg/ml
Detailed Information
Contraindications
**4.3 Contraindications** - Known or suspected carcinoma of the prostate or breast (see section 4.4 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). - Hypersensitivity to the active substance or to any of the excipients, including arachis oil. Sustanon is therefore contraindicated in patients allergic to peanuts or soya (see section 4.4. – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_)
Indication Information
**4.1 Therapeutic indications** Testosterone replacement therapy in male with primary and secondary hypogonadal disorders, (either congenital or acquired) when testosterone deficiency has been confirmed by clinical features and biochemical tests, for example: - After castration, - Eunuchoidism, - Hypopituitarsim, - Endocrine impotence, - Male climacteric symptoms such as decreased libido and decreased mental and physical activity, - Certain types of infertility due to disorders of spermatogenesis In female to male transsexuals: - masculinization.